High doses of imatinib mesylate (800 mg/day) significantly improve rates of major and complete cytogenetic remissions (mcr, ccr) - results from the first planned interim analysis of a multicenter, randomised, 2-arm - phase III study comparing imatinib standard dose (400 mg/day) with imatinib high do

Andreas, A. P.; Bošković, Darinka; Lejniece, S.

Rezultati

eNauka > Rezultati > High doses of imatinib mesylate (800 mg/day) significantly improve rates of major and complete cytogenetic remissions (mcr, ccr) - results from the first planned interim analysis of a multicenter, randomised, 2-arm - phase III study comparing imatinib standard dose (400 mg/day) with imatinib high do

Naziv:	High doses of imatinib mesylate (800 mg/day) significantly improve rates of major and complete cytogenetic remissions (mcr, ccr) - results from the first planned interim analysis of a multicenter, randomised, 2-arm - phase III study comparing imatinib standard dose (400 mg/day) with imatinib high do
Autori:	Andreas, A. P.; Bošković, Darinka; Lejniece, S.
Godina:	2008
Publikacija:	Haematologica
ISSN:	0390-6078 Haematologica Pretraži identifikator
Izdavač:	Pavia : Fondazione Ferrata Storti
Tip rezultata:	Konferencijski rad
Kolacija:	br. Vol. 93 str. 162-162
VBS COBISS:	1024764853
URI:	https://plus.cobiss.net/cobiss/sr/sr/bib/1024764853#izum.si https://enauka.gov.rs/handle/123456789/705479
M-kategorija:	Mp kategorija će biti prikazana naknadno.

Pronađi DOI

Pronalaženje DOI u servisu CrossRef-u na osnovu meta-podataka u zapisu. Prikazaće se DOI (i metapodaci) čiji se podaci najviše poklapaju. OPREZ - to ne mora biti ta publikacija.

Google Scholar^TM

Rezultati na eNauka su zaštićeni autorskim pravima i sva prava su zadržana, osim ako nije drugačije naznačeno.